U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07096921) titled 'The Effect of Two Prokinetics in Patients With Functional Dyspepsia' on July 21.
Brief Summary: This prospective, double-blinded, randomized, multicenter study will compare the efficacy and safety of two prokinetic regimens in patients with Rome IV-diagnosed functional dyspepsia. Ninety-two patients will be randomized (1:1) to receive either mosapride 5 mg + DA-9701 30 mg or mosapride 5 mg + matching placebo, three times daily before meals for 4 weeks. The primary endpoint is the proportion of overall responders ("much improved" or "very much improved" on a 7-point Likert scale) at Week 4. Secondary endpoints include overall response...